CLLS
Price
$2.83
Change
+$0.06 (+2.17%)
Updated
Aug 22, 04:35 PM (EDT)
Capitalization
298.42M
80 days until earnings call
TGTX
Price
$29.45
Change
+$0.68 (+2.36%)
Updated
Aug 22, 04:59 PM (EDT)
Capitalization
4.56B
69 days until earnings call
Interact to see
Advertisement

CLLS vs TGTX

Header iconCLLS vs TGTX Comparison
Open Charts CLLS vs TGTXBanner chart's image
Cellectis SA
Price$2.83
Change+$0.06 (+2.17%)
Volume$100
Capitalization298.42M
TG Therapeutics
Price$29.45
Change+$0.68 (+2.36%)
Volume$34.8K
Capitalization4.56B
CLLS vs TGTX Comparison Chart in %
Loading...
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLLS vs. TGTX commentary
Aug 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and TGTX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2025
Stock price -- (CLLS: $2.77 vs. TGTX: $28.77)
Brand notoriety: CLLS and TGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLLS: 24% vs. TGTX: 74%
Market capitalization -- CLLS: $298.42M vs. TGTX: $4.56B
CLLS [@Biotechnology] is valued at $298.42M. TGTX’s [@Biotechnology] market capitalization is $4.56B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.91B to $0. The average market capitalization across the [@Biotechnology] industry is $1.85B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLLS’s FA Score shows that 1 FA rating(s) are green whileTGTX’s FA Score has 1 green FA rating(s).

  • CLLS’s FA Score: 1 green, 4 red.
  • TGTX’s FA Score: 1 green, 4 red.
According to our system of comparison, CLLS is a better buy in the long-term than TGTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLLS’s TA Score shows that 3 TA indicator(s) are bullish while TGTX’s TA Score has 5 bullish TA indicator(s).

  • CLLS’s TA Score: 3 bullish, 5 bearish.
  • TGTX’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, TGTX is a better buy in the short-term than CLLS.

Price Growth

CLLS (@Biotechnology) experienced а -3.15% price change this week, while TGTX (@Biotechnology) price change was +3.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.19%. For the same industry, the average monthly price growth was +13.95%, and the average quarterly price growth was +27.28%.

Reported Earning Dates

CLLS is expected to report earnings on Nov 10, 2025.

TGTX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TGTX($4.57B) has a higher market cap than CLLS($298M). CLLS YTD gains are higher at: 53.889 vs. TGTX (-4.419). TGTX has higher annual earnings (EBITDA): 97.6M vs. CLLS (-30.25M). TGTX has more cash in the bank: 252M vs. CLLS (196M). CLLS has less debt than TGTX: CLLS (94.8M) vs TGTX (254M). TGTX has higher revenues than CLLS: TGTX (454M) vs CLLS (56.3M).
CLLSTGTXCLLS / TGTX
Capitalization298M4.57B7%
EBITDA-30.25M97.6M-31%
Gain YTD53.889-4.419-1,220%
P/E RatioN/A75.71-
Revenue56.3M454M12%
Total Cash196M252M78%
Total Debt94.8M254M37%
FUNDAMENTALS RATINGS
CLLS vs TGTX: Fundamental Ratings
CLLS
TGTX
OUTLOOK RATING
1..100
223
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
83
Overvalued
PROFIT vs RISK RATING
1..100
10085
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
3564
P/E GROWTH RATING
1..100
1009
SEASONALITY SCORE
1..100
4250

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLLS's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for TGTX (83). This means that CLLS’s stock grew somewhat faster than TGTX’s over the last 12 months.

TGTX's Profit vs Risk Rating (85) in the Biotechnology industry is in the same range as CLLS (100). This means that TGTX’s stock grew similarly to CLLS’s over the last 12 months.

TGTX's SMR Rating (100) in the Biotechnology industry is in the same range as CLLS (100). This means that TGTX’s stock grew similarly to CLLS’s over the last 12 months.

CLLS's Price Growth Rating (35) in the Biotechnology industry is in the same range as TGTX (64). This means that CLLS’s stock grew similarly to TGTX’s over the last 12 months.

TGTX's P/E Growth Rating (9) in the Biotechnology industry is significantly better than the same rating for CLLS (100). This means that TGTX’s stock grew significantly faster than CLLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLLSTGTX
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 12 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LDNXF131.283.81
+2.99%
London Stock Exchange Group plc
MEHCQ3.780.08
+2.16%
23andMe Holding Co.
TRRSF29.640.15
+0.51%
Trisura Group Ltd
FCODF1721.94N/A
N/A
COMPAGNIE DE L ODET
CCTC0.37-0.04
-10.84%
Catalyst Crew Technologies Corp.